Viral Vectors: The Backbone Of Cell And Gene Therapy

Viral vectors are the indispensable delivery system driving the clinical success of cell and gene therapies (CGTs), yet their complexity makes them the single most critical chokepoint in the therapeutic pipeline. The industry’s ability to scale is currently limited by the efficient manufacturing of the two dominant platforms: AAV and lentiviral vectors (LVV).

Understanding the fundamental trade-offs between these systems is essential for strategic development. While AAV is often preferred for in vivo applications due to its low immunogenicity, LVV underpins the vast majority of durable cell modification programs like CAR-T. As the CGT landscape expands into more prevalent indications, overcoming systemic bottlenecks—including process variability and heightened regulatory scrutiny—is crucial. Learn how industrialized, clinic-ready manufacturing processes are required to translate discovery into reliable, patient-ready treatments.

Get a detailed look at navigating the technical and operational constraints of vector production.